SDC1 and COVID-19: A number of studies show that the EGL is damaged in severe COVID-19 patients and the increased plasma levels of glycocalyx components, such as syndecan-1, heparan sulphate, and hyaluronan, were observed as biomarkers, accompanied with high levels of IL-1β, IL-6, TNF-α, hsCRP, and procalcitonin, increasing the risk for COVID-19 severity and mortality [26,27,28,29].